When, if ever, would you re-challenge with immunotherapy for patients with metastatic RCC?  

How are you incorporating CONTACT-03 data presented at #ASCO2023 (Pal et al., PMID 37290461) into your practice? Would you consider immunotherapy re-challenge for someone on adjuvant pembrolizumab? What about for someone whose last immunotherapy exposure was >1 year ago?

Answer from: Medical Oncologist at Academic Institution